Netramark Holdings Inc · TSX:AIAI
Netramark — Investor Presentation (March 2026)
22 slides from Netramark's investor presentation, March 2026
Slide 1: Precision AI that helps life science companies identify the patients driving clinical trial success
Precision AI that helps life science companies identify the patients driving clinical trial success C O R P O R AT E P R E S E N TAT I O N TSX: AIAI OTCQB: AINMF FRA: PF0
Slide 2: Disclaimer
2 IMPORTANT – YOU MUST READ THE FOLLOWING BEFORE CONTINUING: The information contained in this CAUTIONARY NOTE REGARDING FUTURE-ORIENTED FINANCIAL INFORMATION: To the extent any forward-looking statement in presentation has been prepared by NetraMark Holdings Inc. (“NetraMark” or the “Company”) and
Slide 3: Risk Factors
3 RISK FACTORS: There are a number of risk factors as set out below that could cause future results of the Company to differ materially from those described herein. The risks and uncertainties described herein are not the only ones the Company faces. Additional risks and uncertainties, including tho
Slide 4: Drug development challenges
Drug development challenges: Current late-stage trial fail rates - currently up to 65%* Identifying responders in small datasets is difficult Millions of dollars lost in failed trial costs U.S. FDA approval rates sit at <12%* 4 *Source: Chart Pack Biopharmaceuticals in Perspective Fall 2020
Slide 5: The Problem – Clinical Trial Failure
THE PROBLEM – CLINICAL TRIAL FAILURE Late-stage trial failure – often driven by enrolling the wrong patient population, resulting in signal dilution and reduced statistical power. DRUG POST-APPROVAL BASIC PRE- FDA DISCOVERY CLINICAL TRIALS RESEARCH & MONITORING RESEARCH CLINICAL REVIEW PHASE 1 PHASE
Slide 6: Significant Market Opportunity
SIGNIFICANT MARKET OPPORTUNITY Rapid AI growth in healthcare anticipated by 2029 AI IN HEALTHCARE GLOBAL CLINICAL TRIAL (IN USD BILLIONS)2 SUPPORT SERVICES AI in healthcare: $20.9B (2024) to (IN USD BILLIONS)1 $148B (2029) 7.2% 47.1 Clinical trials: 400K+ cumulative3 48.1% 148.4 CAGR CAGR $47B suppo
Slide 7: The Solution - Netra AI
THE SOLUTION - NETRA AI NetraMark’s differentiation is not data access but how the data are analyzed together NetraAI has the potential to Many platforms can ingest identify specific patients driving multiple data types. Very few the outcome of a clinical trial– actually learn patient structure reve
Slide 8: NetraAI Parallel – The Stereogram
NETRAAI PARALLEL – THE STEREOGRAM 8
Slide 9: How NetraAI Is Different from Traditional Methods
HOW NETRAAI IS DIFFERENT FROM TRADITIONAL METHODS Trial outcome: drug candidate works or it doesn’t Outstanding questions to investigate post trial: “Why does the drug work better in some patients than others?” TRADITIONAL ANALYSIS NetraAI ANALYSIS Hypothesis-generating only Helps explain why the tr
Slide 10: The Defensible Moat
THE DEFENSIBLE MOAT TECHNOLOGY MOAT INSTITUTIONAL MOAT Proprietary mathematical FDA engagement and framework alignment Purpose built for small, Peer-reviewed validation heterogeneous clinical CRO partnership datasets First mover advantage Client-protected learning models 10
Slide 11: Why Netra AI Meets FDA Needs
WHY NETRA AI MEETS FDA NEEDS Regulatory milestone – FDA Critical Path Innovation Meeting (CPIM) Dec 4, 2025 - Completed a CPIM with the FDA • Discussed NetraAI for enrichment • Discussed NetraAI for stratification • FDA supportive of exploring model-informed drug development meeting pathway • SAP st
Slide 12: Proven Results: Pancreatic Cancer
PROVEN RESULTS: PANCREATIC CANCER Clinical validation example – stratified chemotherapy response in pancreatic cancer 28 26 12
Slide 13: The Team
THE TEAM George Achilleos Josh Spiegel Dr. Joseph Geraci Chief Executive Officer President Chief Technology Seasoned business executive with 25+ years of experience in finance, Officer/Chief Scientific 25+ years of experience in the sales and corporate strategy, with a Officer and Director technolog
Slide 14: Commercialization
COMMERCIALIZATION Primary revenue driver: Phase 2 readout analysis leading to Phase 3 trial decisions Commercial Direct clients → $200–300K per 6-week engagement strategy Channel partners → embedded in CRO bids Research → validation + credibility U.S. FDA → regulatory alignment 14
Slide 15: Revenue Model
REVENUE MODEL How contracts form: Why this scales: Direct client engagements and CRO-led Multiple revenue events per asset 1. Phase 2 readout work programs 2. Follow-on Phase 3 stratification / SAP support • Typical contract size: U.S. $200K–$300K 3. Expansion across indications / arms (services-bas
Slide 16: More on Direct to Clients
MORE ON DIRECT TO CLIENTS Direct route to market momentum The direct client channel focuses on engaging pharmaceutical and biotech companies without intermediaries KEY HIGHLIGHTS: Growing demand: Proposal phase : Repeat contracts: Growing value contracts: 40+ opportunities 5+ in current 10 repeat co
Slide 17: Channel Partners
CHANNEL PARTNERS Channel partner momentum Worldwide Clinical Trials (“Worldwide”): • Execution of a master services agreement and completed QA review as of October of 2025 with Worldwide Clinical Trials • NetraMark can now be actively included in Worldwide’s Phase 2 and Phase 3 bids across CNS and o
Slide 18: Research Collaborations
RESEARCH COLLABORATIONS Scientific pipeline - validation, credibility, and scientific access NIMH LEADING U.S. ACADEMIC MEDICAL CENTER 18
Slide 19: Peer Reviewed Publications
PEER REVIEWED PUBLICATIONS Peer-reviewed publications NPJ DIGITAL MEDICINE Nature portfolio publication: • On December 8, 2025, NetraMark announced that its scientific study highlighting NetraAI was accepted for publication in npj Digital Medicine, part of the Nature portfolio. • The peer-reviewed p
Slide 20: Summary
SUMMARY FDA reviewed and aligned AI platform High growth High-margin, scalable services model potential Deployable SAP stratification engine NetraMark is building the AI infrastructure Demonstrated across CNS & oncology for precision clinical trials Embedded in CRO workflows Peer-reviewed validation
Slide 21: Tale of the Tape
TALE OF THE TAPE Shares Outstanding1 91.8 million 52-week range 1 $1.10-$0.80 Market Cap1 $85 million Insider ownership2 22 million (fully diluted) 1. Source – TMX Money, as of Feb.24, 2026 2. As of March 6, 2026 21
Slide 22: Thank you
Thank you For more information, please contact george@netramark.com 22
NetraMark Holdings — Investor Presentation (March 2026) on 6ix